Philips (NYSE:PHG) and Masimo (Nasdaq:MASI) today announced that they expanded their patient monitoring partnership to home telehealth applications. The companies extended their partnership to augment patient monitoring capabilities at home with the Masimo W1 watch. The advanced health-tracking watch first launched to early adopters in May 2022. It holds CE mark approval while FDA clearance […]
Patient Monitoring
How Dexcom aims to extend its mission beyond diabetes
CEO Kevin Sayer explains how, following the launch of the next-generation Dexcom G7, the company is looking toward the future. Dexcom (Nasdaq:DXCM) ended 2022 strong, receiving FDA clearance for its next-generation G7 continuous glucose monitor (CGM). With a U.S. launch imminent, the company could keep its efforts centered on the diabetes space. Instead, the company […]
Diabeloop, EOFlow partner on wearable automated insulin delivery in Europe
Diabeloop and EOFlow announced that they partnered to offer the latter’s EOPatch system with automated insulin delivery in Europe. This partnership combines the EOPatch, a third-party continuous glucose monitor (CGM) and Diabeloop’s automated insulin delivery algorithm. They all integrate into Diabeloop’s currently under-development smartphone app. Paris-based Diabeloop said in a news release that they also […]
Masimo wins round in patent spat with Apple
Masimo (Nasdaq:MASI) announced that a U.S. Administrative Law Judge in Washington, D.C. ruled in its favor in a patent spat with Apple. The U.S. International Trade Commission must now consider whether to implement an import ban on Apple Watches, Masimo said in a news release posted last night. MASI shares were up more than 3% […]
CardiacSense wins FDA clearance for medical-grade watch
CardiacSense announced today that it received FDA clearance for its CSF-3 watch for measuring a handful of vital signs. The watch measures beat-by-beat heart rate and oxygen saturation of arterial hemoglobin (SpO2). Caesarea, Isreal-based CardiacSense received CE mark approval for four indications for the watch in February 2021. That approval included continuous AFib monitoring and […]
FDA grants breakthrough nod to patient monitor for organ failure from Opticyte
Opticyte announced today that its Cell O2 patient monitor received breakthrough device designation from the FDA. Seattle-based Opticyte designed Cell O2 to use noninvasive optical spectroscopy technology. It measures and detects systemic low oxygen levels inside cells. This provides continuous monitoring of cellular oxygen levels during hospitalization. The startup said in a news release it […]
Dexcom appoints former J&J exec as CCO, sets 2023 guidance
Dexcom (Nasdaq:DXCM) announced today that it appointed Teri Lawver to its newly created role of chief commercial officer (CCO). Lawver’s position oversees the global commercial organization at the continuous glucose monitoring (CGM) technology developer. She holds responsibility for global sales, marketing and customer experience. Before joining San Diego-based Dexcom, Lawver spent two decades in a […]
Know Labs wins new glucose monitoring patent
Know Labs (NYSE:KNW) announced today that it received a new patent equating its diagnostic technology to the current glucose monitoring standard. Seattle-based Know Labs develops the Bio-RFID technology. It uses spectroscopy to direct electromagnetic energy through a substance or material to capture a unique molecular signature. It integrate into wearable, mobile or bench-top form factors. […]
Study backs use of Masimo hemoglobin monitoring during cesarean delivery
Masimo (Nasdaq:MASI) today announced positive data from a study of its hemoglobin monitoring for patients undergoing cesarean section. The study observed patients undergoing elective cesarean section (CS) with antepartum hemorrhage. Researchers used noninvasive, continuous hemoglobin monitoring with Masimo SpHb. The study demonstrated significant positive correlations between SpHb and invasive hemoglobin (Hb) values. “In patients undergoing […]
HeartBeam expects FDA to approve AIMI system for acute care settings in 2023
In a letter to shareholders, HeartBeam (Nasdaq:BEAT) founder and CEO Branislav Vajdic laid out potential regulatory timelines for 2023. Calling 2022 “a transformative year,” Vajdic updated the expectations for HeartBeam’s AIMIGo and AIMI systems. The company designed AIMIGo as a credit card-sized, 12-lead 3D vector electrocardiogram (ECG) device. It developed AIMI for acute care settings. […]
The 10 biggest diabetes tech stories from 2022
2022 represented a landmark year for next-generation diabetes tech. Here are the biggest stories from the past year. Some companies picked up major regulatory nods. Others experienced major regulatory setbacks. Partnerships were formed and ended, while mergers and acquisitions came and went. There were many stories to choose from in the world of diabetes tech, […]